Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-108110
Filing Date
2025-08-13
Accepted
2025-08-13 16:45:48
Documents
68
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q none-20250630.htm   iXBRL 10-Q 1921550
2 EX-31.1 none-ex31_1.htm EX-31.1 16710
3 EX-31.2 none-ex31_2.htm EX-31.2 14259
4 EX-32.1 none-ex32_1.htm EX-32.1 6899
5 EX-32.2 none-ex32_2.htm EX-32.2 6904
6 GRAPHIC img185803353_0.jpg GRAPHIC 5225
  Complete submission text file 0000950170-25-108110.txt   8295064

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT none-20250630.xsd EX-101.SCH 1429610
71 EXTRACTED XBRL INSTANCE DOCUMENT none-20250630_htm.xml XML 1307332
Mailing Address 66 WELLINGTON STREET WEST, SUITE 5300 TD BANK TOWER BOX 48 TORONTO A6 M5K 1E6
Business Address 66 WELLINGTON STREET WEST, SUITE 5300 TD BANK TOWER BOX 48 TORONTO A6 M5K 1E6 310-849-8060
Aptose Biosciences Inc. (Filer) CIK: 0000882361 (see all company filings)

EIN.: 000000000 | State of Incorp.: A6 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-32001 | Film No.: 251212422
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)